Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.46 |
| ▸ | RAB9A | P51151 | 8/20 | 0.45 |
| ▸ | NPC1 | O15118 | 6/20 | 0.45 |
| ▸ | MAPT | P10636 | 5/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.41 |
| ▸ | RELA | Q04206 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3464344 | 0.98 | CYP1A2 (0.47) | CYP1A2CYP3A4CYP2C9CYP2C19CYP2D6 | |
| SCHEMBL9059236 | 0.83 | CYP1A2 (0.46) | CYP1A2CYP3A4CYP2C9CYP2C19CYP2D6 | |
| SCHEMBL11492524 | 0.82 | NPC1 (0.42) | ALDH1A1RAB9ANPC1MAPTKMT2A | |
| Hydrochloric Acid SCHEMBL28652475 | 0.80 | ALDH1A1 (0.42) | ALDH1A1RAB9ANPC1MAPTKMT2A | |
| SCHEMBL24436849 | 0.79 | TDP1 (0.57) | CYP1A2CYP3A4CYP2C9CYP2C19CYP2D6 | |
| SCHEMBL5840849 | 0.79 | CYP1A2 (0.50) | CYP1A2CYP3A4CYP2C9CYP2C19CYP2D6 | |
| SCHEMBL29418001 | 0.78 | POLB (0.48) | CYP1A2CYP3A4CYP2C9CYP2C19CYP2D6 | |
| SCHEMBL18346160 | 0.78 | CA12 (0.39) | CYP1A2CYP3A4CYP2C9CYP2C19CYP2D6 | |
| SCHEMBL824198 | 0.78 | POLB (0.48) | CYP1A2CYP3A4CYP2C9CYP2C19CYP2D6 | |
| Hydrochloric Acid SCHEMBL28901909 | 0.77 | CYP1A2 (0.49) | CYP1A2CYP3A4CYP2C9CYP2C19CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3623372-B1 | PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | VALO HEALTH INC (US) | 2026-02-04 | — | — | EP | disclosed |
| WO-2021078023-A1 | SMALL MOLECULE COMPOUND | 嘉兴特科罗生物科技有限公司 | 2021-04-29 | — | — | WO | disclosed |
| EP-3313837-B1 | CARBOLINE ANTIPARASITICS | ZOETIS SERVICES LLC (US) | 2020-09-09 | — | — | EP | disclosed |
| EP-3623372-A1 | PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | Forma Therapeutics, Inc. (US) | 2020-03-18 | — | — | EP | disclosed |
| US-10570129-B2 | Carboline antiparasitics | ZOETIS SERVICES LLC (US) | 2020-02-25 | — | — | US | disclosed |
| US-20200031822-A1 | CARBOLINE ANTIPARASITICS | ZOETIS SERVICES LLC (US) | 2020-01-30 | — | — | US | disclosed |
| EP-3240791-B1 | PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | FORMA THERAPEUTICS INC (US) | 2019-11-06 | — | — | EP | disclosed |
| US-10377760-B2 | Pyrrolo and pyrazolopyrimidines as ubiquitin-specific protease 7 inhibitors | FORMA THERAPEUTICS, INC. (US) | 2019-08-13 | — | — | US | disclosed |
| US-20180339988-A1 | PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | VALO HEALTH, INC. | 2018-11-29 | — | — | US | disclosed |
| EP-3313837-A1 | CARBOLINE ANTIPARASITICS | Zoetis Services LLC (US) | 2018-05-02 | — | — | EP | disclosed |
| US-7737154-B2 | CRF receptor antagonists and methods relating thereto | SMITHKLINE BEECHAM (CORK) LIMITED (IE) | 2010-06-15 | — | — | US | disclosed |
| US-7737154-B2 | CRF receptor antagonists and methods relating thereto | SMITHKLINE BEECHAM (CORK) LIMITED (IE) | 2010-06-15 | — | — | US | disclosed |
| US-7652035-B2 | CRF receptor antagonists and methods relating thereto | Neurocrine Bioscience, Inc. (US) | 2010-01-26 | — | — | US | disclosed |
| US-7652035-B2 | CRF receptor antagonists and methods relating thereto | Neurocrine Bioscience, Inc. (US) | 2010-01-26 | — | — | US | disclosed |
| US-20080064719-A1 | Crf Receptor Antagonists And Methods Relating Thereto | SMITHKLINE BEECHAM (CORK) LIMITED (IE) | 2008-03-13 | — | — | US | disclosed |
| US-20080064719-A1 | Crf Receptor Antagonists And Methods Relating Thereto | SMITHKLINE BEECHAM (CORK) LIMITED (IE) | 2008-03-13 | — | — | US | disclosed |
| US-20070293511-A1 | Crf Receptor Antagonists and Methods | SB PHARMCO PUERTO RICO INC. AND NEUROCRINE BIOSCIENCES, INC., A CORPORATION | 2007-12-20 | — | — | US | disclosed |
| US-20070293511-A1 | Crf Receptor Antagonists and Methods | SB PHARMCO PUERTO RICO INC. AND NEUROCRINE BIOSCIENCES, INC., A CORPORATION | 2007-12-20 | — | — | US | disclosed |
| US-20070287705-A1 | Crf Receptor Antagonists and Methods Relating Thereto | NEUROCRINE BIOSCIENCES, INC. | 2007-12-13 | — | — | US | disclosed |
| US-20070287705-A1 | Crf Receptor Antagonists and Methods Relating Thereto | NEUROCRINE BIOSCIENCES, INC. | 2007-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10377760-B2 | Pyrrolo and pyrazolopyrimidines as ubiquitin-specific protease 7 inhibitors | USP7, UBA7, UBXN1 | CYP1A2 2080/4885CYP3A4 1757/4885CYP2C9 2518/4885 |
| US-20070293511-A1 | Crf Receptor Antagonists and Methods | CRHR1, CRHR2, CRH | CYP1A2 977/4885CYP3A4 1101/4885CYP2C9 634/4885 |
| US-20070287705-A1 | Crf Receptor Antagonists and Methods Relating Thereto | CRHR1, CRHR2, CRH | CYP1A2 842/4885CYP3A4 803/4885CYP2C9 553/4885 |
| US-20080064719-A1 | Crf Receptor Antagonists And Methods Relating Thereto | CRHR1, CRHR2, SCTR | CYP1A2 868/4885CYP3A4 704/4885CYP2C9 636/4885 |
| US-10570129-B2 | Carboline antiparasitics | ADRA1D, DRD1, CHRM1 | CYP1A2 47/4885CYP3A4 294/4885CYP2C9 652/4885 |
| US-20180339988-A1 | PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | USP7, UBA7, UBXN1 | CYP1A2 2080/4885CYP3A4 1757/4885CYP2C9 2518/4885 |
| US-20200031822-A1 | CARBOLINE ANTIPARASITICS | DRD1, ADRA1D, DRD2 | CYP1A2 47/4885CYP3A4 270/4885CYP2C9 570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.